Skip to main content
Premium Trial:

Request an Annual Quote

Congenica Receives $1.6M in Seed Funding

NEW YORK (GenomeWeb) – Bioinformatics firm Congenica today announced it has received £1 million ($1.6 million) from Cambridge Innovation Capital to scale up its Sapientia platform.

Sapientia is a modular and scalable data analytics tool for annotating and clinically interpreting genomic sequence data.

"Sapientia combines clinical information about the patient, information about their gene mutations, and background information about the disease phenotypes of other patients with those mutations," Matthew Hurles, co-founder of Congenica, said in a statement. "We have worked very closely with clinical geneticists to ensure that Sapientia can present this information in a way that is easy for clinicians to interpret."

The technology improves the diagnosis of rare genetic diseases, the Hinxton, UK-based firm said in a statement, and could provide future insights into the screening and treatment of rare and common diseases.

In May, the firm received £200,000 to further develop the platform.

"We see Congenica's technology as a powerful enabler that can realize the potential for a radically different type of genome analysis service," said Cambridge Innovation Capital's Robert Tansley. 

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.